OptiSeq™ Pan-Cancer Panel Service (65-Gene)

Sample to report within 10 business days

DiaDiaCarta offers a sample-to-report OptiSeq™ Targeted Sequencing cancer service at its state-of-the-art facility. The liquid biopsy/FFPE sample prep workflow provides clients with fast turnaround time and accurate VAF detection process. Variants are classified based on guidelines with a focus on actionable content from drug labels and clinical trials. Information is presented in a final report. The whole process from samples (blood/FFPE) to report is completed within 10 business days in our laboratory.

OptiSeq™ Pan-Cancer Panel is designed to target 2,900 commonly observed mutational positions (hotspots) from 65 oncogenes and tumor suppressor genes. This panel contains a single pool of 601 primer pairs and the average amplicon length is 145 bp – perfectly suitable for ctDNA and FFDNA sequencing.

OptiSeq™ Pan-Cancer Gene Panel (65 Genes)


Advantages of OptiSeq™ Pan-Cancer Panel

samples tested

Liquid biopsy (blood/ccfDNA) and FFPE samples (tissue/DNA)  

highly sensitive

Highly sensitive NGS test allows as low as 1% variant allele frequency (VAF) detection

Fast turnaround time

Sample receipt to clinical report within 10 days. No deep sequencing  

Extremely uniform

100% observed uniformity at ≥ 0.2X mean depth and 97% observed uniformity at ≥ 0.5X

Low dna input needed

10ng for detection of somatic mutations (SNP); 100pg for germline mutations

Report to Clinicians

Comprehensive clinically significant variants, FDA-approved therapies and clinical trials

OptiSeq™ Pan-Cancer Panel Service Sample Report

The research NGS report also includes information regarding variant details, FDA-approved therapies for this indication, therapies associated with resistance, clinical trials, genes tested, methods and limitations, and selected citations.

Streamlined Workflow for OptiSeq™ Pan-Cancer Panel

Step 1: Sample prep & QC

Step 2: Target enrichment

Step 3: Library Preparation & QC & Template

Step 4: Sequencing Run

Step 5: Data Analysis

Step 6: Reporting

OptiSeq™ Pan-Cancer Panel Specifications

Sample Type

Liquid biopsy (blood/cfDNA) and FFPE samples (tissue/DNA)



Recommended DNA Input (Amount)

10ng for detection of somatic mutations (SNP); 100pg for germline mutations

Sequencing Platform

Illumina Sequencers (MiniSeq, MiSeq, NextSeq, HiSeq)

Enrichment Method

Multiplex PCR

Number of Primer Pairs


Number of Primer Pools


Number of Target Genes


Target Region Size (bp)


Amplicon Size

Average 146bp (from 125-175bp)

Sample Multiplexing (at ~2000x mean coverage)

Miseq 2×150 Read Length: ~25 samples
NextSeq Series Mid Output 2×150 Read Length: ~200
NextSeq Series High Output @ 2×150 Read Length: ~600

Coverage Uniformity (at ~ ≥ 0.2x Mean Coverage)

> 95%

On-target Reads % (% reads aligned to target regions out of total aligned reads)

> 95%

Turnaround Time

Sample receipt to report within 10 days


Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!